Innovation in Cardiovascular Care at MedAxiom's CV Transforum
Elite Cardiovascular Leaders Unite: Driving Innovation Through Shared Excellence
Oak Ridge, TN – Daxor Corporation (NASDAQ: DXR), a leader in blood volume measurement technology, proudly announces its participation at the MedAxiom Cardiovascular (CV) Transforum Fall’24 Conference. This prestigious event is set to occur at the Gaylord Rockies Resort & Convention Center, where cardiovascular experts and industry leaders will gather to share insights and innovations that enhance cardiovascular care.
Daxor’s presence at this conference marks a significant opportunity to connect with prominent figures in cardiovascular medicine. "We are excited to engage with fellow innovators and showcase how our blood volume analysis technology addresses critical challenges faced in healthcare, such as reducing hospital readmissions and improving patient survival rates. MedAxiom has a proven track record of fostering collaborations that lead to impactful solutions, making it the perfect venue for us to highlight our technology," stated Michael Feldschuh, CEO and President of Daxor Corporation.
Impact of BVA Guided Care on Patient Outcomes
The BVA guided care approach has been validated through peer-reviewed studies, displaying remarkable improvements in patient outcomes. Significant findings include an 82% reduction in 30-day mortality, a 56% decrease in 30-day hospital readmissions, and an impressive 57% reduction in hospital length of stay when BVA testing is conducted upon patient admission (P<0.001). This technology equips healthcare professionals with highly accurate data—boasting 98% accuracy—to optimize treatment plans tailored to individual patient needs, thereby enhancing both outcomes and cost-effectiveness.
Understanding Daxor Corporation's Mission
Daxor Corporation (NASDAQ: DXR) is dedicated to revolutionizing patient care through its innovative blood volume measurement technology. The company has introduced the BVA-100, the only FDA-cleared diagnostic blood test that delivers precise and objective quantification of blood volume status in comparison to patient-specific norms. This technology has successfully conducted over 65,000 tests across leading hospitals, demonstrating a significant positive impact on performance metrics across various medical and surgical settings.
With strong evidence indicating improvements in mortality and readmissions for heart failure and critical care, Daxor is actively involved in several clinical trials focusing on heart failure treatments, backed by support from the NIH. In addition, the company is collaborating with the U.S. Department of Defense to enhance combat casualty care through advanced analyzers, underlining its commitment to optimal fluid management in healthcare.
Join Daxor on Their Journey
Daxor's vision extends to ensuring optimal blood volume for everyone, which it achieves through innovative testing and analysis. For healthcare professionals and institutions looking for advanced solutions in patient management, Daxor maintains a dedicated platform where individuals can stay updated about new technologies and advancements in this medical field.
For more detailed information about Daxor Corporation, its technologies, and opportunities to engage with the company, interested parties are encouraged to visit their official webpage. With continuous advancements and support from both the healthcare community and federal agencies, Daxor is at the forefront of improving care quality through science and technology.
Frequently Asked Questions
What is Daxor Corporation known for?
Daxor Corporation is known for its pioneering blood volume measurement technology, specifically the BVA-100 diagnostic tool.
When is the MedAxiom CV Transforum event taking place?
The MedAxiom CV Transforum is occurring from October 17-19, 2024.
How does BVA guided care impact patient outcomes?
BVA guided care has demonstrated improvements such as an 82% reduction in 30-day mortality and a 56% reduction in hospital readmissions.
Is Daxor involved in any clinical trials?
Yes, Daxor is conducting several clinical trials focusing on heart failure treatments, supported by the NIH.
How can I stay updated with Daxor's innovations?
Individuals can visit Daxor’s official website to sign up for updates on their latest technologies and advancements in healthcare.
